

Board Renewal

Melbourne, Australia – 1 June 2026: [Adherium Limited](#) (ASX:ADR), a global leader in digital respiratory management and developer of the FDA-cleared Hailie® Smartinhaler® platform is pleased to announce changes to the positions of Chair and Non-Executive Directors of the Company effective from today, 1 June 2026.

Mr George Baran, currently a Non-Executive Director of the Company and Executive Chair of Company's largest shareholder, Trudell Medical Limited, will assume the role of Non-Executive Chair of Adherium Limited. The Trudell Group has operating companies active in digital health and manufacturing of respiratory devices for global markets.

Mr Lou Panaccio, who has held the position of Chair since April 2022, remains on the Board as Lead Independent Non-Executive Director providing a seamless transition with his expertise and knowledge of the Company. Mr Panaccio will become the Chair of the Risk and Audit and Nomination and Remuneration Committees, which to date have been chaired by Mr Bruce McHarrie.

As recently announced, Mr Bruce McHarrie retires from the Board effective 31 May 2026. The Board is pleased to advise that Ms Victoria Durrans, who has been acting as an Alternate Director to Mr Jeremy Curnock Cook since March 2026, has been appointed as a Non-Executive Director in her own right. Ms Durrans is a Partner in the investment team at BioScience Managers focused on building high-growth technology companies globally.

Finally, the Board wishes to thank Mr Panaccio for his services as the Company's Chair and Mr McHarrie for his commitment and contribution to Company during his 11-year tenure.

- ENDS -

This ASX announcement was approved and authorised for release by the Board of Adherium.

Investor Enquiries

Adherium Limited
investors@adherium.com

Media Enquiries:

Haley Chartres
HACK Director
haley@hck.digital



ASX Release

About Adherium (ASX: ADR):

Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices, with more than 180,000 sold globally. Adherium's Hailie® platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management. The Hailie® solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium's own broad range of sensors connected to respiratory medications. Adherium's Hailie® solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease. Learn more at [adherium.com](https://www.adherium.com)

About Hailie® Smartinhaler®

Hailie® Smartinhaler® devices attach to commonly used inhalers to capture and transmit inhalation event data, enabling patients and care teams to understand medication-use patterns and support earlier, more proactive interventions.